Dishman Carbogen reveals new insights for Vit D deficiency in COVID-19 patients

image credit- shutterstock

Announces successful results from the partnership with Boston University School of Medicine

Ahmedabad-based Dishman Carbogen Amcis, a global outsourcing partner for the pharmaceutical industry, has announced the results of a new clinical research study which shows that oral 25- Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte percentages.

The research was supervised by Tehran University of Medical Sciences and Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly owned subsidiary CARBOGEN AMCIS B.V. 

“The COVID-19 pandemic hitting the world in early 2020 resulted in unprecedented global focus of R&D efforts and of solidarity in coping with the sudden and unexpected high need for intensive care beds, which didn’t hit all countries to the same degree”, said Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis.

“It is important for us to play a role in this new challenge, not only for our corporate interests but to contribute to the possible future of the fight against COVID-19. Therefore, to follow up with this Clinical Research Study, Dishman Carbogen Amcis is currently conducting a second round of study in a larger scale in India”, he added.





Read Previous

McCain Foods invests $55 M in Strong Roots for growth in plant-based sector

Read Next

US FDA releases improvement plan on foodborne outbreak response

Leave a Reply